Aligos Therapeutics (ALGS) FCF Margin (2021 - 2026)
Aligos Therapeutics (ALGS) reported FCF Margin of 817.24% for Q1 2026, up 590591.0% on a YoY basis from N/an in Q1 2025, and up 93.65% quarter-over-quarter from 12866.86% in Q4 2025.
Aligos Therapeutics (ALGS) FCF Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported FCF Margin for 6 years, with the latest figure at 817.24% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 590591.0% year-over-year to 817.24%; the trailing twelve-month figure through Mar 2026 stood at 1800.68% (up 64374.0% YoY), and the FY2025 full-year result was 3774.15%, down 153452.0% from the prior year.
- FCF Margin for Q1 2026 stood at 817.24%, up from 12866.86% in the prior quarter.
- The five-year high for FCF Margin was 317.09% in Q2 2023, with the low at 12866.86% in Q4 2025.
- Historically, FCF Margin has averaged 2604.82% across 5 years, with a median of 1606.63% in 2025.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 982702 bps — and 2025, when it tumbled 983007 bps.
- Aligos Therapeutics' FCF Margin stood at 477.07% in 2022, then retreated by 24 bps to 593.3% in 2023, then slumped by 412 bps to 3036.8% in 2024, then sank by 324 bps to 12866.86% in 2025, then surged by 94 bps to 817.24% in 2026.
- The last three FCF Margin figures came in at 817.24% (Q1 2026), 12866.86% (Q4 2025), and 3285.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -817.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -817.24% |
| Dec 31, 2025 | -12,866.86% |
| Sep 30, 2025 | -3,285.43% |
| Jun 30, 2025 | -1,606.63% |
| Mar 31, 2025 | -6,723.15% |
| Dec 31, 2024 | -3,036.80% |
| Sep 30, 2024 | -1,608.08% |
| Jun 30, 2024 | -1,837.23% |
| Mar 31, 2024 | -3,277.52% |
| Dec 31, 2023 | -593.30% |
| Sep 30, 2023 | -944.10% |
| Jun 30, 2023 | -317.09% |
| Mar 31, 2023 | -866.98% |
| Dec 31, 2022 | -477.07% |
| Mar 31, 2022 | -814.82% |
| Dec 31, 2021 | -10,304.09% |
| Sep 30, 2021 | -1,656.80% |
| Jun 30, 2021 | -1,499.68% |
| Mar 31, 2021 | -3,308.02% |